Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease.
- Author:
Ho Cheol KIM
1
;
Jung Su LEE
;
Sang Hyung KIM
;
Hoon Sub SO
;
Chang Yoon WOO
;
Jae Lyun LEE
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jaelyun@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Von Hippel-Lindau disease;
Neoplasm metastasis;
Renal cell carcinoma;
Sunitinib
- MeSH:
Carcinoma, Renal Cell*;
Central Nervous System;
Humans;
Neoplasm Metastasis;
Prognosis;
Protein-Tyrosine Kinases;
von Hippel-Lindau Disease*
- From:Cancer Research and Treatment
2013;45(4):349-353
- CountryRepublic of Korea
- Language:English
-
Abstract:
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
